Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
Medtronic
Johnson and Johnson
McKesson

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR PF-04965842


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for PF-04965842

Trial ID Title Status Sponsor Phase Summary
NCT01835197 ↗ First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects Completed Pfizer Phase 1 This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects.
NCT02163161 ↗ AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects Completed Pfizer Phase 1 Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects.
NCT02201524 ↗ Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis Terminated Pfizer Phase 2 Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.
NCT02780167 ↗ Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed Pfizer Phase 2 Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for PF-04965842

Condition Name

Condition Name for
Intervention Trials
Healthy 9
Dermatitis, Atopic 6
Atopic Dermatitis 3
Dermatitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Dermatitis 9
Dermatitis, Atopic 9
Eczema 8
Hypersensitivity, Immediate 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PF-04965842

Trials by Country

Trials by Country for
Location Trials
United States 175
Canada 38
China 38
United Kingdom 30
Australia 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Florida 11
Texas 9
Indiana 9
California 9
Virginia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PF-04965842

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 6
Phase 2 3
Phase 1 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 21
Terminated 1
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PF-04965842

Sponsor Name

Sponsor Name for
Sponsor Trials
Pfizer 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Express Scripts
Harvard Business School
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.